The future of Indian Pharmaceuticals in the Post-COVID Era

At the peak of the crisis, over-stretched healthcare organisations are battling to save lives and control infection rates, while also protecting their frontline staff. Less prominent is the seismic impact that COVID-19 is having on the regular day-to-day operations of the pharma industry. With so much time and resources being allocated to the pandemic, every aspect of the pharma value chain from manufacturing to sales and marketing is having to adapt. The reality is that working practices across the industry may never be the same again. But as the coronavirus pandemic requires social distancing and a rapid search for a vaccine, it could finally be the trigger that forces a traditionally risk-averse industry beholden to legacy systems, regulation and compliance to fully embrace new technology. This discussion will bring perspective on real world examples of how different organizations reacted during these difficult times and how global pharma organizations are embracing the transformation to enhance the experience during this crisis.

Speakers

Anand K
Chief Executive Officer
SRL

Arvind Kukrety
Deputy Drug Controller
Central Drug Standard Control Organization (CDSCO)

Karan Singh
Managing Director
ACG

Shri Navdeep Rinwa
Joint Secretary (Policy, Medical Device, Pharma Bureau), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers

Omar Sherief Mohammad
Managing Director
Roche Diabetes Care India

Prashant Nagre
Chief Executive Officer
Fermenta Biotech

Sanjiv Navangul
Managing Director & CEO
Bharat Serums and Vaccines

Vikas Bhadoria
Senior Partner
McKinsey & Company

Vikrant Shrotriya
Managing Director and Corporate Vice President
Novo Nordisk

Moderator
Vikas Dandekar
Editor (Pharma & Healthcare)
The Economic Times Prime

Agenda

17:00 – 17:05	Welcome & Introduction by The Economic Times
17:05 – 17:15	Keynote: The future of Indian Pharmaceuticals in the Post-COVID Era
	Karan Singh, Managing Director and Balajikasiram S, Group Chief Digital Officer, ACG
17:15 – 18:15	A New Prescription: How COVID-19 has changed Global Healthcare and what the outbreak means for the industry?
	At the peak of the crisis, over-stretched healthcare organisations are battling to save lives and control infection rates, while also protecting their frontline staff. Less prominent is the seismic impact that COVID-19 is having on the regular day-to-day operations of the pharma industry. With so much time and resources being allocated to the pandemic, every aspect of the pharma value chain from manufacturing to sales and marketing is having to adapt. The reality is that working practices across the industry may never be the same again. But as the coronavirus pandemic requires social distancing and a rapid search for a vaccine, it could finally be the trigger that forces a traditionally risk-averse industry beholden to legacy systems, regulation and compliance to fully embrace new technology. Months of the pandemic! A lot has happened - from fears of raw material supply disruptions to expedited approval of repurposed medicines and now hopes pinned on vaccines. Just sometime into this ‘new normal’, it is also clear that digital tech will have a pivotal role to play in ensuring that the pharma industry continues to function to the best of its abilities, providing both healthcare practitioners (HCPs) and patients with the vital support they need. This discussion will bring perspective on real world examples of how different organizations reacted during these difficult times and how global pharma organizations are embracing the transformation to enhance the experience during this crisis: Healthcare and supply chain issues that have emerged from COVID Pharma’s role in India’s journey towards Atmanirbharta (Self-Reliance) Leveraging digital to enhance health outcomes and patient experiences to unlock growth and maximize impact across internal and external engagements Understanding the dynamics of future customer engagements – Driving a personalized customer experience What are the main ways the global Covid-19 pandemic has transformed Pharma companies’ digital strategies? Championing change within the organization towards a digital future Driving digital innovation capabilities through partnerships What will it take to build a self-reliant ecosystem of pharma manufacturers, drug producers and healthcare providers? Innovation in healthcare – telemedicine, e-pharmacy, e-consulting Future Trends - Rise of nutraceutical industry; Biotech vaccines; personalization of medicine. *Featured Speakers:* Sanjiv Navangul, Managing Director & CEO, Bharat Serums and Vaccines Navdeep Rinwa, Joint Secretary (Policy, Medical Device, Pharma Bureau), Department of Pharmaceuticals Arvind Kukreti, Deputy Drug Controller, Central Drug Standard Control Organization (CDSCO) Karan Singh, Managing Director, ACG Worldwide Omar Sherief Mohammad, Managing Director, Roche Diabetes Care India Prashant Nagre, Chief Executive Officer, Fermenta Biotech Anand K, Chief Executive Officer, SRL Vikas Bhadoria, Senior Partner, McKinsey & Company Vikrant Shrotriya, Managing Director and Corporate Vice President, Novo Nordisk *Panel Moderator:* Vikas Dandekar, Editor – Pharma & Healthcare – The Economic Times
18:15 – 18:25	Interactive Q&A with Audience
18:25 - 18:30	Closing Remarks